Pattern recognition, using a group of characteristic, or discriminating features, is a powerful tool in metabolic diagnostic. A classic example of this approach is used in biochemical analysis of urine organic acid analysis, where the reporting depends more on the correlation of pertinent positive and negative findings, rather than on the absolute values of specific markers. Similar uses of pattern recognition in the field of biochemical genetics include the interpretation of data obtained by metabolomics, like glycomics, where a recognizable pattern or the presence of a specific glycan sub-fraction can lead to the direct diagnosis of certain types of congenital disorders of glycosylation. Another indispensable tool is the use of clinical pattern recognition-or syndromology-relying on careful phenotyping. While genomics might uncover variants not essential in the final clinical expression of disease, and metabolomics could point to a mixture of primary but also secondary changes in biochemical pathways, phenomics describes the clinically relevant manifestations and the full expression of the disease. In the current review we apply phenomics to the field of congenital disorders of glycosylation, focusing on recognizable differentiating findings in glycosylation disorders, characteristic dysmorphic features and malformations in PMM2-CDG, and overlapping patterns among the currently known glycosylation disorders based on their pathophysiological basis.
Introduction
A phenotype is the set of all observable characteristics of an organism. The etymology of the word stems from the Greek word Bphainein^(to show) and Btypos^(type) or Bvisible type^. Phenotyping is the oldest practice used by physicians to diagnose disease. Syndromology is a specific way of phenotyping, using a group of signs and symptoms that occur together to characterize a particular abnormality or condition. Patients born with an inborn error of metabolism can present with a genetic syndrome, showing a set of concurrent findings that form an identifiable pattern, even if the symptoms vary in severity. Congenital disorders of glycosylation (CDG) belong to a rapidly expanding group of metabolic disorders, frequently present as Bsyndromes^ (Jaeken and Péanne 2017) . In fact, they were initially discovered as a novel disease group based on careful phenotyping of the most frequent form, now known as PMM2-CDG, where patients show dysmorphic facial features, strabismus, inverted nipples, abnormal fat distribution and a variable combination of endocrine abnormalities and coagulation defects, making the disorder recognizable. Since the description of PMM2-CDG there have been more than 130 CDG subtypes described, and the number of disorders is rapidly growing. A few of these disorders are treatable, and Responsible Editor: Marc Patterson Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10545-018-0156-5) contains supplementary material, which is available to authorized users. therefore early diagnosis is very important (Dörre et al 2015; Riley et al 2017) . Some subtypes are detectable by transferrin isoform screening or other forms of glycosylation analysis, helping the diagnostic crusade (Buczkowska et al 2015; Bengtson et al 2016) . But is there a specific clinical pattern in CDGs, which could point the clinician towards the correct diagnosis? In the current era of next-generation sequencing, is there a role for the clinician, or will the art of phenotyping succumb to molecular techniques in the -omics era? In this mini-review we structured all subtypes of CDGs described to date according to their biochemical nosology, and then attempt to establish a correspondence between certain subtypes with overlapping phenotypes and their biochemical basis. Finally, we review the existing literature on the phenotypic features associated with PMM2-CDG, and present data on computer-aided phenotyping by means of facial recognition analysis. We propose that the art of phenomics, either as performed by clinicians or with the help of currently-available technologies, continues to be very much alive, and rather than being supplanted by other -omics, it's complementary to these.
Methods
A literature review was performed for each individual disorder of glycosylation, and a table was created with all subtypes of glycosylation disorders described to date. Each subtype of CDG was individually evaluated, and a concise summary was performed on those disorders that were felt to have clinical, imaging or laboratory findings that allow recognition and distinction from other disorders.
Next, a literature review was performed on congenital malformations in PMM2-CDG, using a PubMed search. PubMed database search was performed using the following terms: Congenital disorder(s) of glycosylation, type Ia OR PMM2 OR PMM2-CDG OR phosphomannomutase 2 deficiency OR Jaeken syndrome OR CDG-Ia OR carbohydrate deficient glycoprotein syndrome plus anomaly OR malformation OR malformation OR dysmorphic. All the publications were included in the search from the time of the disorder discovery, i.e. 1980. Only patients with confirmed PMM2 mutations or enzymaticallyconfirmed phosphomannomutase 2 deficiency were included.
A total of 165 papers were reviewed. Reported cases were collected and summarized in an Excel table (Suppl . Table 1 ). In total, 561 patients were reported in the literature with confirmed PMM2-CDG.
Finally, we performed facial recognition analysis using the Facial Dysmorphology Novel Analysis (FDNA, Boston MA, USA) technology, which allows for assessment of subtle craniofacial dysmorphic features and facial pattern recognition. The input consisted of 53 facial frontal photos from 50 unaffected controls, as well as photos of 18 patients with confirmed PMM2-CDG. A binary comparison was then performed between groups, and the capacity to distinguish them was assessed by measuring the area under the curve (AUC) of the receiver operating characteristic (ROC) curve, which plots the true positive rate as a function of the true negative rate. An AUC of 1 indicates perfect accuracy, while an AUC of 0.5 is the performance obtained by a totally random system (as for example a coin toss). Cross validation was performed by recurrently and randomly splitting the data into training sets, each set containing half of the photos. This random split was repeated 10 times (Lumaka et al 2017) .
Results

Nosology of congenital disorders of glycosylation
We created a nosology of all currently described CDGs, classified according to their pathophysiology (see Table 1) Recognizable phenotypes in congenital disorders of glycosylation (Type 1 serum transferrin N-hypoglycosylation pattern: *, type 2 N-hypoglycosylation pattern: **, O-linked hypoglycosylation#, GPI-anchoring deficiency ##)
MPI-CDG*
MPI-CDG presents with liver disease (hepatomegaly and hepatopathy, cirrhosis), coagulopathy (increased bleeding tendency and risk for thrombotic episodes), hyperinsulinemic hypoglycemia, and gastrointestinal symptoms (chronic diarrhea, protein-losing enteropathy). It is treatable by mannose (200 mg/ kg 4-6 times a day). Some patients need liver transplantation. There is normal intellectual development.
PMM2-CDG*
PMM2-CDG is the most common N-glycosylation abnormality. Strabismus, large ears, thin upper lip, inverted nipples, abnormal fat distribution and developmental delay (intellectual disability in most cases) are characteristic. Coagulation abnormalities, thrombotic events, stroke-like episodes, hepatopathy and endocrine abnormalities are not detectable in all patients, although hypogonadism is prevalent. Cerebellar hypoplasia can be present as early as the neonatal period.
GFPT1-CDG, DPAGT1-CDG*, ALG14-CDG, ALG2-CDG * All of these subtypes can present with disordered neurotransmission in the form of myasthenia. In addition, DPAGT1-CDG and ALG2-CDG can present with a multisystemic disorder. ALG6-CDG* and ALG8-CDG* Patients with ALG6-CDG have developmental disability, proximal muscle weakness, seizures and in most cases ataxia. Brachydactyly and finger malformations have been described in several patients. ALG8-CDG is also accompanied by brachydactyly, as well as intellectual disability and dysmorphic features including low-set ears, hypertelorism, and macroglossia.
ALG3-CDG*, ALG9-CDG* and ALG12-CDG*
The severe form of ALG9-CDG (Gillessen-Kaesbach-Nishimura syndrome) is accompanied by polycystic kidneys, hepatic fibrosis, congenital heart disease and characteristic skeletal changes including mesomelia, a round pelvis, shortened sacrosciatic notch and ovoid ischia, hypomineralization of skull, cervical vertebral bodies, and pubic rami and thick occipital bone. Similar skeletal anomalies were described in ALG3-CDG and ALG12-CDG.
MGAT2-CDG**
MGAT2-CDG is a disorder with recognizable facial features (long eyelashes, prominent nasal bridge, underdeveloped alae nasi, low-hanging columella, thin vermillion of the upper lip, thick vermillion of the lower lip). This disease is also characterized by severe growth delay, mental disability with absent speech and in some patients, radio-ulnar synostosis.
MAN1B1-CDG**#
MAN1B1-CDG is a Golgi CDG with intellectual disability and, in most patients, facial dysmorphism (widely spaced eyes with down-slanting palpebral fissures, long ears, underdeveloped naso-labial fold, thin vermillion of the upper lip) and truncal obesity.
SRD5A3-CDG*
SRD5A3-CDG is a syndromal form of a dolicholphosphate synthesis defect; patients have eye malformations (cataract, retinal anomalies, glaucoma, visual loss), cerebellar ataxia and in about one third of the cases ichthyosiform skin anomalies. Developmental disability is mostly severe.
DOLK-CDG*
DOLK-CDG is usually associated with a multisystem phenotype, with neurologic, endocrine and coagulation abnormalities. A discriminative feature is dilated cardiomyopathy. Milder cases benefit from early cardiac transplantation.
DPM1-CDG*, DPM2-CDG* and DPM3-CDG* All of these subtypes lead to alpha-dystroglycan hypoglycosylation, elevated creatine kinase levels and muscle d y s t r o p h y. U n l i k e o t h e r p h e n o t y p e s o f a l p h adystroglycanopathies, patients with either of these three forms of CDG also show abnormal transferrin glycosylation in serum.
COG1-CDG** COG1-CDG patients show variable phenotypic features and variable severity. Some patients have been described with a costo-cerebro-mandibular-like syndrome.
COG7-CDG**
COG7-CDG is recognizable in most patients based on microcephaly, growth impairment, adducted thumbs, ventricular septal defect and episodes of hyperthermia.
SLC35C1-CDG**
SLC35C1-CDG is a disorder with frequent infections, neutrophilia and distinct facial features including brachycephaly, low insertion of the anterior hairline, coarse features, puffy eyelids, flat nasal bridge, large tongue and long upper lip with everted lower lips. Patients also have a rare blood type, the Bombay blood group. The immune phenotype improves with oral fucose supplementation.
ATP6V0A2-CDG**#
ATP6V0A2-CDG is also called autosomal recessive cutis laxa type 2A (ARCL2A). Generalized congenital sagging skin, cutis laxa, abnormal fat distribution, motor developmental disability, skeletal abnormalities, short stature and joint luxation are characteristic. Intellectual development can be normal. Cutis laxa improves with age. Some patients have cobblestone-like brain dysgenesis and seizures.
ATP6V1A-CDG and ATP6V1E1-CDG**# ATP6V1A-CDG and ATP6V1E1-CDG patients are very similar to those diagnosed with ATP6V0A2-CDG. They have generalized cutis laxa, motor and intellectual developmental disability, cardiac involvement and hypercholesterolemia. Cutis laxa improves with age.
ATP6AP1-CDG and ATP6AP2-CDG**# ATP6AP1-CDG and ATP6AP2-CDG both present with early liver disease (cholestasis, fibrosis, cirrhosis). Frequent infections are mostly associated with hypogammaglobulinemia. Early symptoms include cutis laxa, which disappears with age.
TMEM199-CDG and CCDC115-CDG**# TMEM199-CDG and CCDC115-CDG also present with early liver disease (cholestasis, fibrosis, cirrhosis) as well as hypercholesterolemia, low serum ceruloplasmin and developmental disability. These conditions can mimic Wilson disease, given the liver disease with hypoceruloplasminemia. Liver transplantation is a therapeutic option.
TMEM165-CDG**#
TMEM165-CDG is a recognizable spondyloepimetaphyseal skeletal dysplasia with extreme osteopenia, short stature, hyperinsulinism, growth hormone deficiency and variable intellectual disability. Galactose treatment (1 g/kg/day) showed biochemical improvement of glycosylated proteins in blood.
SLC39A8-CDG**#
SLC39A-CDG is a multisystem disorder with seizures. Several patients show a skeletal dysplasia with rhizomelic shortening and dwarfism. Not all patients have abnormal transferrin isoform analysis. Laboratory examinations, however, reveal low blood manganese and zinc concentrations, with increased urinary concentration from renal wasting. Patients show clinical and biochemical improvement on galactose (1 g/kg/day) and individually dosed oral manganese therapy.
PGM1-CDG*/** PGM1-CDG is a disorder with midline malformations (Pierre-Robin sequence, bifid uvula, cleft palate), hepatopathy, muscle weakness, cardiomyopathy and hypoglycaemia. This is an unusual CDG in that the type 2 transferrin pattern hides a combined type 1/type 2 defect. Galactose treatment (1 g/kg/ day) showed biochemical improvement of blood glycoproteins and liver function tests.
GMPPA-CDG
GMPPA-CDG is accompanied by alacrima, achalasia and intellectual disability. Although NGLY1 deficiency can have alacrima and intellectual disability, patients do not have achalasia. Triple A syndrome can present alacrima and achalasia, but patients also have adrenal insufficiency, not seen in GMPPA-CDG.
PIGA-CDG##
PIGA-CDG presents with multiple congenital malformations, depressed nasal bridge, coarse face, hypotonia, infantile seizures and elevated serum alkaline phosphatase.
PIGL-CDG##
PIGL-CDG is also known as CHIME syndrome, an acronym that describes its salient features of ocular Colobomas, congenital Heart disease, early-onset Ichthyosis, Mental retardation and Ear anomalies (conductive hearing loss).
PIGM-CDG##
PIGM-CDG is characterized by portal vein thrombosis and seizures. The seizures can improve with sodium butyrate, which increases transcription.
Phenotype of PMM2-CDG
The following congenital anomalies were reported in patients with confirmed PMM2-CDG.
Strabismus
Strabismus was described in 290 of 395 patients (73%). In the available case series of 10 or more patients, the frequency of strabismus has been variably reported as 36 of 56 patients, or 64% ( 
Inverted nipples
Inverted nipples were seen in 183 of 343 patients (53%). In the available case series of 10 or more patients, the frequency of inverted nipples has been variably reported as five of 20 patients, or 25% ( 
Abnormal fat distribution
Abnormal fat distribution was reported in 168 out of 357 patients (47%). In the available case series of 10 or more patients, the frequency of abnormal fat distribution has been variably reported as five of 20 patients, or 25% ( 
Dysmorphic facial features
Dysmorphic features have been described in large series in 29% of 66 patients (Pérez et al 2011 ), 11 of 20, or 55% (de Lonlay et al 2001 , and 24 of 37, or 65% of patients (Barone et al 2015) , including a prominent forehead, large ears and ear lobules, thin upper lip, prominent jaw and long and slender fingers and toes. The prominent jaw develops over time, as the mandible can start as retrognathic (Al-Maawali et al 2014). Almond-shaped eyes have also been frequently described, including in seven of a series of 13 patients (Serrano et al 2015) . Other features reported in more than single patients include skin/peau d'orange in seven (Clayton et al 1992; Vabres et al 1998; de Michelena et al 1999; Stark et , narrow/short palpebral fissures in three (Truin et al 2008; Işıkay et al 2014) , epicanthal folds in two (Tayebi et al 2002; Enns et al 2002) , prominent nose in two (Barone et al 2008; Thong et al 2009) and anteverted nares in two (Tayebi et al 2002; Morava et al 2004) . Other features variably reported included hypertelorism in two (Edwards et al 2006; Kasapkara et al 2017) , but hypotelorism in two (Pavone et al 1996) ; downslanted palpebral fissures in three (Clayton et al 1992; Bubel et al 2002) , while others had upslanted palpebral fissures (Kjaergaard et al 2001; Brum et al 2008) ; flat nasal bridge in five (Harding et al 1988; Tayebi et al 2002; Thong et al 2009; Al-Maawali et al 2014; Kasapkara et al 2017) , but high nasal bridge in four (Artigas et al 1998; Antoun et al 1999; Laplace et al 2003) . A coarse face has been described in older adults (Bortot et al 2013; Barone et al 2015) .
Congenital cardiac malformations
Conotruncal heart defects were described in a few patients, including tetralogy of Fallot in three patients (Vermeer et al 2007; Romano et al 2009; Al Teneiji et al 2017) , while common arterial trunk (also known as truncus arteriosus) was reported in two (Romano et al 2009; Serrano et al 2015 , Marques-da-Silva et al 2017b Congenital airway and lung malformations.
No malformations have been reported so far in PMM2-CDG patients.
Congenital liver and bile duct malformations
No liver and bile duct malformations have been reported so far in PMM2-CDG patients. Fibrotic changes and bile duct dilatation described in a few cases appeared later during the course of disease compared to other CDGs, like MPI-CDG (Marques-da-Silva et al 2017a).
Congenital urogenital malformations
Hydrocele, inguinal hernia and/or cryptorchidism was seen in 10 of 12 boys in one series (Kjaergaard et al 2001) , while cryptorchidism was described in four other patients (Veneselli et al 1998; Garel et al 1998; Truin et al 2008; Resende et al 2014) . The most commonly reported malformations were multicystic kidneys, reported in 17 patients (13 detected by ultrasound, three by renal biopsy and one by autopsy) followed by enlarged kidney size in four patients and hydronephrosis in one patient (Schiff et 
Facial recognition analysis of PMM2-CDG
For the facial phenotypic analysis of patients with PMM2-CDG, a composite image of unaffected controls vs that of patients can be found in Fig. 1a,b . Facial recognition analysis allowed for the discrimination of patients with PMM2-CDG vs controls, with an AUC of 0.84 (p value 0.014, see Fig. 1c,d ).
Discussion
We define the PMM2-CDG phenotype, which is recognizable in at least 50% of the patients based on the presence of strabismus, inverted nipples, and abnormal fat distribution. However, not only the inverted nipples and abnormal fat distribution, but also the facial phenotype seems to be recognizable among patients with PMM2-CDG. In particular, commonly reported facial dysmorphic features included almondshaped eyes, large ears in relation to the (variably) decreased head circumference, a thin vermillion of the upper lip, short nose with long, smooth philtrum and over time also prognathism. Although not reported in the literature, deep-set eyes and high-arched eyebrows are also often found in the authors' experience. Another dysmorphic finding frequently reported in the literature is arachnodactyly.
It is easy to understand why patients with mutations in genes involved in similar pathways would have similar symptoms. For example, it is understandable that mutations in 12 genes involved in the O-glycosylation of alpha-dystroglycan would all lead to a similar phenotype of muscular dystrophy, since glycosylation is essential for the anchoring function of dystroglycan (Endo 2015) . However, by the same token it is hard to explain how mutations in certain genes involved in Nglycosylation could lead to such discrepant phenotypes. Since the transfer of the lipid-linked oligosaccharide (LLO) from the dolichol carrier to the nascent protein in the ER happens en bloc, in theory a deficiency of any of the 14 enzymes involved in the synthesis of the LLO would lead to a similar clinical presentation, as all would lead to the same deficient Nglycosylation of the nascent protein. However, this is not the case, and the phenotypes appear to be clustered instead. For example, a defect in the synthesis of UDP-GlcNAc (as in GFPT1-CDG) or proteins participating in the addition of the first or second GlcNAc to the LLO (DPAGT1-and ALG14-CDG, respectively) all cause a similar phenotype of congenital myasthenic syndrome (Wu et al 2003; Senderek et al 2011; Cossins et al 2013) . A defect in the addition of the fourth and fifth mannoses (ALG11-CDG) and of the immediate next step of flipping the LLO from the cytoplasmic to the luminal side of the ER (RFT1-CDG) both lead to sensorineural hearing loss, a finding that is otherwise quite rare in other types of Fig. 1 Facial recognition analysis of patients with PMM2-CDG. a Composite photo created by averaging the extracted mathematical information of the photos in the control cohort. b Composite photo obtained from images of patients with PMM2-CDG. c Score distribution of the binary comparison between unaffected controls and patients with PMM2-CDG. d ROC curve with pertinent statistics obtained after conducting 10 random splits (true positive rate on the ordinate, true negative rate on abscissa) CDG (Vleugels et al 2009a; Rind et al 2010; Regal et al 2015) . Defects in the addition of the last four mannoses in the luminal side of the ER (ALG3-CDG, ALG9-CDG and ALG12-CDG) are associated with very characteristic skeletal changes, defined by mesomelic brachymelia, round pelvis, shortened sacrosciatic notch and ovoid ischia, hypomineralization of the skull, cervical vertebral bodies, pubic rami and a thick occipital bone (Tham et al 2016) . These skeletal findings are not similar to those seen in any of the other CDGs. Finally, defects in the next two steps in the synthesis of the LLO, meaning the addition of the first (ALG6-CDG) and second (ALG8-CDG) Glc lead to brachydactyly (Höck et al 2015; Morava et al 2016) , while the most common type of CDG is associated with the opposite phenotype of long and slender fingers and toes. See Fig. 2 for a diagram depicting the aforementioned enzymatic steps.
This clustering of phenotypes is puzzling, since again all of these steps occur prior to the en bloc transfer of the glycan chain to the protein. The explanation for this phenotype clustering can thus not solely be related to protein hypoglycosylation. One possibility is that the accumulated LLOs themselves, or modifications of these, could in some way be toxic. For example, the cytosolic accumulation of Man3GlcNAc2-PP-Dol or Man4GlcNAc2-PP-Dol could lead to damage of the inner ear cells, while ER accumulation of Man5GlcNAc2-PP-Dol to Man8GlcNAc2-PP-Dol could lead to a reproducible skeletal dysplasia, and ER accumulation of Man9GlcNAc2-PP-Dol or GlcMan9GlcNAc2-PP-Dol would lead to brachydactyly as opposed to arachnodactyly. Alternatively, it is possible that the pathogenesis of these disorders is not only related to protein hypoglycosylation, but also to protein misglycosylation with truncated LLOs, since it is known that these truncated LLOs can indeed be transferred to the nascent protein, although with decreased efficiency (Krasnewich et al 1995; Panneerselvam and Freeze 1996; Vleugels et al 2009b) . Even in the latter scenario, proteins that are misglycosylated with specific truncated LLOs as above could lead to the clustered phenotypes described.
It is clear that our understanding of the pathophysiologic mechanisms leading to the different phenotypes seen in CDG patients is still poor. However, the rapid scientific advances that ushered in the next-generation sequencing should not deter us from careful patient phenotyping, the oldest tool in the physician's armamentarium. Next-generation sequencing should lead to next-generation phenotyping, and the different -omics should be complementary with the process of phenomics. 
